JPWO2019175215A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175215A5 JPWO2019175215A5 JP2020547415A JP2020547415A JPWO2019175215A5 JP WO2019175215 A5 JPWO2019175215 A5 JP WO2019175215A5 JP 2020547415 A JP2020547415 A JP 2020547415A JP 2020547415 A JP2020547415 A JP 2020547415A JP WO2019175215 A5 JPWO2019175215 A5 JP WO2019175215A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- composition
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims 34
- 102000004965 antibodies Human genes 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 17
- 102000038129 antigens Human genes 0.000 claims 17
- 108091007172 antigens Proteins 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 101700082799 IL2RA Proteins 0.000 claims 5
- 102100002950 ISG20 Human genes 0.000 claims 5
- 101700015336 ISG20 Proteins 0.000 claims 5
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 3
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 230000002489 hematologic Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000000779 depleting Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642243P | 2018-03-13 | 2018-03-13 | |
| US201862642248P | 2018-03-13 | 2018-03-13 | |
| US201862642232P | 2018-03-13 | 2018-03-13 | |
| US201862642218P | 2018-03-13 | 2018-03-13 | |
| US201862642230P | 2018-03-13 | 2018-03-13 | |
| GB1804027.9 | 2018-03-13 | ||
| PCT/EP2018/056312 WO2018167104A1 (fr) | 2017-03-17 | 2018-03-13 | Anti-cd25 à optimisation fc pour épuisement de cellules spécifiques tumorales |
| EPPCT/EP2018/056312 | 2018-03-13 | ||
| US62/642,230 | 2018-03-13 | ||
| GBGB1804029.5A GB201804029D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| US62/642,243 | 2018-03-13 | ||
| US62/642,232 | 2018-03-13 | ||
| GBGB1804027.9A GB201804027D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| US62/642,218 | 2018-03-13 | ||
| GBGB1804028.7A GB201804028D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| GB1804028.7 | 2018-03-13 | ||
| GB1804029.5 | 2018-03-13 | ||
| US62/642,248 | 2018-03-13 | ||
| PCT/EP2019/056247 WO2019175215A1 (fr) | 2018-03-13 | 2019-03-13 | Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515568A JP2021515568A (ja) | 2021-06-24 |
| JPWO2019175215A5 true JPWO2019175215A5 (fr) | 2022-03-18 |
Family
ID=67903878
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547332A Active JP7565797B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547332A Active JP7565797B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Country Status (14)
| Country | Link |
|---|---|
| US (11) | US11919960B2 (fr) |
| EP (8) | EP3765502B1 (fr) |
| JP (8) | JP7474701B2 (fr) |
| KR (3) | KR20200131286A (fr) |
| CN (8) | CN112020513B (fr) |
| AU (3) | AU2019233575A1 (fr) |
| BR (3) | BR112020016499A2 (fr) |
| CA (3) | CA3088659A1 (fr) |
| CR (3) | CR20200465A (fr) |
| MA (1) | MA51993A (fr) |
| PE (3) | PE20210287A1 (fr) |
| SG (3) | SG11202008699WA (fr) |
| TW (3) | TW202003034A (fr) |
| WO (8) | WO2019175216A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| CN108795858A (zh) * | 2017-04-28 | 2018-11-13 | 深圳宾德生物技术有限公司 | 高抗癌活性t细胞的筛选方法和应用 |
| EP3765502B1 (fr) | 2018-03-13 | 2024-08-07 | Tusk Therapeutics Ltd | Anticoprs anti cd25 impliquant la déplétion de cellules spécifiques aux tumeurs |
| JP2022538733A (ja) * | 2019-05-20 | 2022-09-06 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 新規抗ｃｄ２５抗体 |
| TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| WO2021228218A1 (fr) | 2020-05-14 | 2021-11-18 | 江苏恒瑞医药股份有限公司 | Anticorps anti-cd25, fragments de liaison à l'antigène associés et utilisations médicales associées |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| KR20230107641A (ko) * | 2020-11-13 | 2023-07-17 | 아이바이오, 인크. | Cd25 항체 |
| US20240002522A1 (en) * | 2020-11-20 | 2024-01-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Anti-cd25 antibodies |
| JP2024504547A (ja) * | 2020-11-20 | 2024-02-01 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 抗ｃｄ２５抗体 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| JP2024505556A (ja) | 2021-02-02 | 2024-02-06 | ラクテン・メディカル，インコーポレイテッド | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 |
| CN116940844A (zh) | 2021-03-01 | 2023-10-24 | 豪夫迈·罗氏有限公司 | 新颖生物标志物及其用途 |
| EP4386000A1 (fr) | 2021-08-09 | 2024-06-19 | Nanjing Novoacine Bio-Technology Co., Ltd. | Anticorps anti-cd25 humain recombinant et son utilisation |
| EP4396230A1 (fr) | 2021-09-02 | 2024-07-10 | F. Hoffmann-La Roche AG | Anticorps pour traiter la lam |
| JP2024532485A (ja) * | 2021-09-03 | 2024-09-05 | ノヴァロック バイオセラピューティクス， リミテッド | Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 |
| WO2023134766A1 (fr) | 2022-01-17 | 2023-07-20 | 诺纳生物（苏州）有限公司 | Anticorps ciblant cd25, son procédé de préparation et son utilisation |
| WO2023208990A1 (fr) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Polythérapie pour le traitement du cancer comprenant un antagoniste de l'axe fas et un antagoniste d'agent de déplétion des lymphocytes t-reg, |
| CN115197321B (zh) * | 2022-06-02 | 2023-08-18 | 四川大学 | 靶向cd25的抗体及其用途 |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| CN115181181B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种抗cd25的单域抗体及其应用 |
| WO2024006965A1 (fr) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps spécifiques de cd25 et leurs utilisations |
| WO2024040195A1 (fr) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditionnement pour l'ingénierie de cellules immunitaires in vivo |
| WO2024088987A1 (fr) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Polythérapie pour le traitement du cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| CN116004636B (zh) * | 2023-01-10 | 2024-03-12 | 广西师范大学 | 一种不结合红细胞的差异化cd47核酸适体及其应用 |
| WO2024165454A1 (fr) | 2023-02-06 | 2024-08-15 | F. Hoffmann-La Roche Ag | Polythérapie et utilisations associées |
| WO2024192065A1 (fr) * | 2023-03-14 | 2024-09-19 | Odyssey Therapeutics, Inc. | Protéines de liaison à l'antigène anti-cd25 et leurs utilisations |
| WO2024204629A1 (fr) * | 2023-03-29 | 2024-10-03 | 第一三共株式会社 | Anticorps anti-cd25 et conjugué anticorps-médicament anti-cd25 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
| EP1578397B1 (fr) | 2002-11-15 | 2012-12-26 | Genmab A/S | Anticorps monoclonaux humains contre cd25 |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| EP1599572A4 (fr) | 2003-02-14 | 2007-06-13 | Univ Southern California | Compositions et methodes pour immunotherapie anticancereuse |
| WO2005123780A2 (fr) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| CN101072578A (zh) | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2008003473A2 (fr) | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions et procédés destinés à améliorer l'efficacité de réponses immunitaires à médiation par il-2 |
| EA201201533A1 (ru) | 2006-08-18 | 2014-11-28 | Новартис Аг | Prlr-специфическое антитело и его применения |
| EP1997832A1 (fr) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| EP2356270B1 (fr) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Bibliothèques combinatoires d'anticorps et leurs utilisations |
| CA2773240C (fr) | 2009-09-22 | 2015-11-10 | Volker Sandig | Procede de production de molecules contenant des structures glycanes specialisees |
| WO2011077245A2 (fr) | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| EP2378287A1 (fr) * | 2010-04-15 | 2011-10-19 | TXCell | Nouveau procédé pour l'isolement de cellules T1 |
| CA2806076A1 (fr) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anticorps-antigenes antitumoraux et methodes d'utilisation correspondantes |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2970486B1 (fr) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation de cellules t avec des anticorps bispecifiques et des fusions fc |
| CN105377892A (zh) * | 2013-03-15 | 2016-03-02 | 艾伯维生物技术有限公司 | 抗cd25抗体及其用途 |
| JP2016514690A (ja) | 2013-03-15 | 2016-05-23 | アッヴィ バイオテクノロジー リミテッド | 抗ｃｄ２５抗体およびそれらの使用 |
| SG10201708143QA (en) * | 2013-06-06 | 2017-11-29 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| WO2015109212A1 (fr) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anticorps anti-il-2 et compositions et utilisations de ceux-ci |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AU2015289621A1 (en) | 2014-07-16 | 2017-01-12 | Genentech, Inc. | Methods of treating cancer using TIGIT inhibitors and anti-cancer agents |
| US10428146B2 (en) * | 2014-07-22 | 2019-10-01 | Cb Therapeutics, Inc. | Anti PD-1 antibodies |
| CA2957387A1 (fr) | 2014-08-07 | 2016-02-11 | Hyogo College Of Medicine | Agent therapeutique contre le cancer contenant une combinaison d'il-18 et d'anticorps de ciblage de molecules |
| US11147652B2 (en) | 2014-11-13 | 2021-10-19 | Align Technology, Inc. | Method for tracking, predicting, and proactively correcting malocclusion and related issues |
| EP3789402B1 (fr) * | 2014-11-20 | 2022-07-13 | F. Hoffmann-La Roche AG | Thérapie de combinaison de molécules de liaison à l'antigène bispécifiques d'activation des lymphocytes t et d'antagonistes de liaison à l'axe pd-1 |
| SG11201703192SA (en) * | 2014-11-21 | 2017-05-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| RU2732042C2 (ru) | 2015-02-19 | 2020-09-10 | Компьюджен Лтд. | Анти-pvrig антитела и способы применения |
| ES2768784T3 (es) * | 2015-03-23 | 2020-06-23 | Bayer Pharma AG | Anticuerpos anti-CEACAM6 y usos de los mismos |
| WO2017070561A1 (fr) * | 2015-10-23 | 2017-04-27 | Pfizer Inc. | Anticorps anti-il-2, compositions les contenant et leurs utilisations |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| SG10201913033UA (en) * | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| CN108752476B (zh) * | 2016-03-04 | 2019-09-20 | 四川科伦博泰生物医药股份有限公司 | 一种pdl-1抗体、其药物组合物及其用途 |
| CN109476739A (zh) | 2016-04-07 | 2019-03-15 | 癌症研究技术有限公司 | 用于肿瘤特异性细胞消减的抗CD25 FCγ受体双特异性抗体 |
| SG11201810525XA (en) * | 2016-06-10 | 2018-12-28 | Regeneron Pharma | Anti-gitr antibodies and uses thereof |
| JP6831651B2 (ja) | 2016-07-04 | 2021-02-17 | 川崎重工業株式会社 | ワークの袋詰め装置 |
| CN110167957A (zh) | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US11119165B2 (en) | 2017-06-28 | 2021-09-14 | North Carolina State University Office of Research Commercialization | Photonic band-gap resonator for magnetic resonance applications |
| JP7225135B2 (ja) | 2017-07-06 | 2023-02-20 | タスク セラピューティクス リミテッド | 腫瘍特異的細胞枯渇のための化合物及び方法 |
| EP3765502B1 (fr) | 2018-03-13 | 2024-08-07 | Tusk Therapeutics Ltd | Anticoprs anti cd25 impliquant la déplétion de cellules spécifiques aux tumeurs |
| MA51997A (fr) | 2018-03-13 | 2021-06-23 | Cancer Research Tech Ltd | Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur |
| KR20200003558A (ko) | 2018-07-02 | 2020-01-10 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치 |
| KR102080909B1 (ko) | 2018-07-06 | 2020-02-24 | 한국수력원자력 주식회사 | 원자로의 해체 시스템 |
-
2019
- 2019-03-13 EP EP19709954.2A patent/EP3765502B1/fr active Active
- 2019-03-13 JP JP2020547371A patent/JP7474701B2/ja active Active
- 2019-03-13 EP EP19709958.3A patent/EP3765506B1/fr active Active
- 2019-03-13 CN CN201980019247.9A patent/CN112020513B/zh active Active
- 2019-03-13 EP EP19711075.2A patent/EP3765510A1/fr active Pending
- 2019-03-13 CN CN201980019248.3A patent/CN112020514B/zh active Active
- 2019-03-13 EP EP19709957.5A patent/EP3765505B1/fr active Active
- 2019-03-13 AU AU2019233575A patent/AU2019233575A1/en not_active Abandoned
- 2019-03-13 WO PCT/EP2019/056248 patent/WO2019175216A1/fr active Application Filing
- 2019-03-13 US US16/979,933 patent/US11919960B2/en active Active
- 2019-03-13 US US16/352,717 patent/US10745485B2/en active Active
- 2019-03-13 BR BR112020016499-2A patent/BR112020016499A2/pt not_active Application Discontinuation
- 2019-03-13 PE PE2020001292A patent/PE20210287A1/es unknown
- 2019-03-13 EP EP19710416.9A patent/EP3765507B1/fr active Active
- 2019-03-13 TW TW108108467A patent/TW202003034A/zh unknown
- 2019-03-13 JP JP2020547399A patent/JP7451415B2/ja active Active
- 2019-03-13 JP JP2020547415A patent/JP2021515568A/ja active Pending
- 2019-03-13 EP EP19709956.7A patent/EP3765504B1/fr active Active
- 2019-03-13 US US16/979,929 patent/US11802161B2/en active Active
- 2019-03-13 PE PE2020001299A patent/PE20210288A1/es unknown
- 2019-03-13 CN CN201980019235.6A patent/CN112041345A/zh active Pending
- 2019-03-13 CR CR20200465A patent/CR20200465A/es unknown
- 2019-03-13 JP JP2020547333A patent/JP7510348B2/ja active Active
- 2019-03-13 SG SG11202008699WA patent/SG11202008699WA/en unknown
- 2019-03-13 CN CN201980019257.2A patent/CN112218891B/zh active Active
- 2019-03-13 US US16/979,931 patent/US11851494B2/en active Active
- 2019-03-13 CA CA3088659A patent/CA3088659A1/fr not_active Abandoned
- 2019-03-13 TW TW108108451A patent/TW201938588A/zh unknown
- 2019-03-13 WO PCT/EP2019/056256 patent/WO2019175222A1/fr active Application Filing
- 2019-03-13 BR BR112020016501-8A patent/BR112020016501A2/pt unknown
- 2019-03-13 MA MA051993A patent/MA51993A/fr unknown
- 2019-03-13 WO PCT/EP2019/056249 patent/WO2019175217A1/fr active Application Filing
- 2019-03-13 AU AU2019233576A patent/AU2019233576A1/en not_active Abandoned
- 2019-03-13 CN CN201980019241.1A patent/CN112020512A/zh active Pending
- 2019-03-13 US US16/352,709 patent/US10752691B2/en active Active
- 2019-03-13 PE PE2020001320A patent/PE20210289A1/es unknown
- 2019-03-13 US US16/979,930 patent/US11814434B2/en active Active
- 2019-03-13 SG SG11202008733YA patent/SG11202008733YA/en unknown
- 2019-03-13 US US16/352,703 patent/US10738125B2/en active Active
- 2019-03-13 CN CN201980019234.1A patent/CN112074536B/zh active Active
- 2019-03-13 WO PCT/EP2019/056252 patent/WO2019175220A1/fr unknown
- 2019-03-13 JP JP2020547332A patent/JP7565797B2/ja active Active
- 2019-03-13 CN CN201980019249.8A patent/CN112020515B/zh active Active
- 2019-03-13 WO PCT/EP2019/056260 patent/WO2019175226A1/fr unknown
- 2019-03-13 US US16/979,935 patent/US11697688B2/en active Active
- 2019-03-13 WO PCT/EP2019/056247 patent/WO2019175215A1/fr unknown
- 2019-03-13 EP EP19711315.2A patent/EP3765511B1/fr active Active
- 2019-03-13 JP JP2020547363A patent/JP7451414B2/ja active Active
- 2019-03-13 TW TW108108452A patent/TW201940515A/zh unknown
- 2019-03-13 CA CA3088246A patent/CA3088246A1/fr not_active Abandoned
- 2019-03-13 CR CR20200466A patent/CR20200466A/es unknown
- 2019-03-13 JP JP2020547326A patent/JP7563978B2/ja active Active
- 2019-03-13 CA CA3088671A patent/CA3088671A1/fr active Pending
- 2019-03-13 WO PCT/EP2019/056257 patent/WO2019175223A1/fr unknown
- 2019-03-13 US US16/979,932 patent/US11873341B2/en active Active
- 2019-03-13 CN CN201980019256.8A patent/CN112020516A/zh active Pending
- 2019-03-13 AU AU2019233581A patent/AU2019233581A1/en active Pending
- 2019-03-13 JP JP2020547331A patent/JP7563979B2/ja active Active
- 2019-03-13 WO PCT/EP2019/056258 patent/WO2019175224A1/fr unknown
- 2019-03-13 KR KR1020207029205A patent/KR20200131286A/ko unknown
- 2019-03-13 KR KR1020207029221A patent/KR20200131861A/ko not_active Application Discontinuation
- 2019-03-13 SG SG11202008784RA patent/SG11202008784RA/en unknown
- 2019-03-13 KR KR1020207029229A patent/KR20200131862A/ko unknown
- 2019-03-13 BR BR112020016519-0A patent/BR112020016519A2/pt not_active Application Discontinuation
- 2019-03-13 EP EP19709955.9A patent/EP3765503B1/fr active Active
- 2019-03-13 CR CR20200467A patent/CR20200467A/es unknown
-
2020
- 2020-02-05 US US16/782,440 patent/US11802160B2/en active Active
- 2020-02-05 US US16/782,461 patent/US11787866B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019175215A5 (fr) | ||
| JPWO2019175226A5 (fr) | ||
| JPWO2019175220A5 (fr) | ||
| JPWO2019175216A5 (fr) | ||
| JPWO2019175217A5 (fr) | ||
| JPWO2019175222A5 (fr) | ||
| Yasunaga | Antibody therapeutics and immunoregulation in cancer and autoimmune disease | |
| JPWO2019175224A5 (fr) | ||
| US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
| Wang et al. | Development of therapeutic antibodies for the treatment of diseases | |
| JPWO2019175223A5 (fr) | ||
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018510636A5 (fr) | ||
| JP2020515247A5 (fr) | ||
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| CA3065951A1 (fr) | Anticorps uniquement a chaines lourdes anti-bcma | |
| JP2020522280A5 (fr) | ||
| JP2020522281A5 (fr) | ||
| Yoon et al. | Current perspectives on therapeutic antibodies | |
| JP2020533965A5 (fr) | ||
| RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
| JP2020531003A5 (fr) | ||
| CN114616245A (zh) | 一种抗cd38的抗体及其用途 |